Hutchinson-Gilford Progeria Syndrome
6
0
0
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
4 treatments under study, led by Progerinin
Research Leaders
5 sponsors active, led by Bundang CHA Hospital
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 4 completed trials
Clinical Trials (6)
Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)
A Study Observing Disease Progression in a Patient With Hutchinson-Gilford Progeria Syndrome (HGPS)
Creating Stem Cells From a Progeria Patient's Blood to Test Candidate Treatments in the Lab
Phase I Study of Progerinin in Healthy Volunteers
Umbilical Cord Blood Transfusion in Progeria Syndrome
Treatment of the Hutchinson-Gilford Progeria Syndrome With a Combination of Pravastatin and Zoledronic Acid
Research Network
Common Treatments
- Progerinin2
- Lonafarnib1
- Sirolimus1
- Zoledronic Acid Pravastatin1
Active Sponsors
- Bundang CHA Hospital3
- PRG Science & Technology Co., Ltd.2
- Assistance Publique Hopitaux De Marseille1
- Korea Research Institute of Bioscience & Biotechnology1
- Amarex Clinical Research1
Top Investigators
Assistance Publique des Hopitaux de Marseille
Related Conditions
- Werner Syndrome1